TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31565753

Group type: EXPERIMENTAL
Intervention: Glutamine (0.9 g kg‐1 fat‐free mass)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 12
Study: 28487249

Group type: EXPERIMENTAL
Intervention: Combination of rightward prismatic adaptation (PA) and anodal transcranial direct current stimulation (tDCS) of the right motor cortex
Number of subjects: 34

Group type: COMPARATOR
Intervention: Rightward prismatic adaptation (PA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Anodal tDCS of the right motor cortex
Number of subjects: 34
Study: 25205323

Group type: EXPERIMENTAL
Intervention: Ferritin concentration (0.29 per log‐mg/dl)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Being an ethnic minority (‐0.24 compared with Kinh)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Number of children (‐0.17)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (0.09)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: RBP (0.27 per mg/dl)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Hookworm infection (‐0.11)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Prevalence of anemia
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Iron deficiency (Fe <12 μg/l)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Insufficient iron stores (Fe<30 μg/l)
Number of subjects: 4986

Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia
Number of subjects: 4986
Study: 23810354

Group type: COMPARATOR
Intervention: Manual lymphatic drainage (MLD) on days 2, 3, and 4 postoperatively
Number of subjects: 43

Group type: COMPARATOR
Intervention: No manual lymphatic drainage (no MLD)
Number of subjects: 43
Study: 21474643

Group type: EXPERIMENTAL
Intervention: Nebulized ceftazidime (15 mg·kg(‐1)·3 h(‐1)) and amikacin (25 mg·kg(‐1)·d(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous ceftazidime (90 mg·kg(‐1)·d(‐1), continuous administration) and amikacin (15 mg·kg(‐1)·d(‐1))
Number of subjects: 40
Study: 18708923

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g preoperative dose)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Cefuroxime and Placebo
Number of subjects: 1237
Study: 16857835

Group type: EXPERIMENTAL
Intervention: L-rhamnose (25 g/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lactulose (25 g/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: D-glucose (control)
Number of subjects: 18
Study: 11827905

Group type: COMPARATOR
Intervention: Amoxicillin (25 mg/kg, twice daily for 5 days)
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (4 mg/kg trimethoprim plus 20 mg/kg sulphamethoxazole, twice daily for 5 days)
Number of subjects: 1471
Study: 10419992

Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A (among malnourished infants)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo (among malnourished infants)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: 30 mg vitamin A (among well-nourished children)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Placebo (among well-nourished children)
Number of subjects: 618
Study: 7570409

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 63
Study: 2111292

Group type: EXPERIMENTAL
Intervention: Mixed diet (1200 kcal/day)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lactovegetarian diet (1200 kcal/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 6767728

Group type: EXPERIMENTAL
Intervention: Helium particles
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Heavy charged particles (carbon, neon, argon ions)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Heavy charged particles (helium, carbon, neon, argon)
Number of subjects: 157
Study: 6344901

Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 8

Group type: COMPARATOR
Intervention: 60 mg glaucine
Number of subjects: 8
Study: 31335248

Group type: EXPERIMENTAL
Intervention: Visits involving discussion of chemotherapy
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Visits involving discussion of terminal prognosis
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Level of service
Number of subjects: 339

Group type: COMPARATOR
Intervention: Provider characteristics (age, sex, years of experience)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Dimensions of work intensity
Number of subjects: 339
Study: 29022754

Group type: EXPERIMENTAL
Intervention: PBM of 830 nm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PBM of 685 nm
Number of subjects: 30
Study: 26708755

Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters, n=55)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 434

Group type: COMPARATOR
Intervention: Smoking reduction (reduced intensity of smoking)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Smoking cessation or reduction
Number of subjects: 434
Study: 24901838

Group type: EXPERIMENTAL
Intervention: Endorectal proctopexy with levatorplasty (ERPP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: STARR procedure
Number of subjects: 66
Study: 22209591

Group type: EXPERIMENTAL
Intervention: Counseling with educational tools
Number of subjects: 261

Group type: COMPARATOR
Intervention: Routine counseling procedures (Control)
Number of subjects: 261
Study: 20434378

Group type: EXPERIMENTAL
Intervention: Individually defined physiotherapy program
Number of subjects: 16

Group type: COMPARATOR
Intervention: General training program
Number of subjects: 16
Study: 19087327

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 64
Study: 16237616

Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cycling (C)
Number of subjects: 13
Study: 11818918

Group type: EXPERIMENTAL
Intervention: Pediatric variable stiffness colonoscope
Number of subjects: 363

Group type: COMPARATOR
Intervention: Pediatric colonoscope
Number of subjects: 363

Group type: COMPARATOR
Intervention: Adult colonoscope
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 363
Study: 10419815

Group type: EXPERIMENTAL
Intervention: mRNA expression of cystic fibrosis (CF) gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mRNA expression of multidrug resistance (MDR1) gene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (other cell types within the villous core)
Number of subjects: 0
Study: 7752174

Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg or 400 mg once daily
Number of subjects: 171

Group type: COMPARATOR
Intervention: metoprolol 100 mg or 200 mg once daily
Number of subjects: 171
Study: 2178765

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents (natural and synthetic tumor suppressive retinoids and antioxidants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candidate chemopreventives
Number of subjects: 0
Study: 6107677

Group type: COMPARATOR
Intervention: Behaviour therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Pharmacotherapy (fenfluramine)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Combination of behaviour therapy and pharmacotherapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 134
Study: 30700250

Group type: EXPERIMENTAL
Intervention: DVD presentation along with standard invitation (letter and information leaflet)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Standard invitation only (letter and information leaflet)
Number of subjects: 1050
Study: 27668928

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 0
Study: 26026615

Group type: EXPERIMENTAL
Intervention: Minimally-tailored group format
Number of subjects: 98

Group type: COMPARATOR
Intervention: Highly tailored, multidisciplinary individual format
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Group format
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Weight concern
Number of subjects: 98
Study: 24037008

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (3 times per week, 40 minutes per session, low-to-moderate intensity)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (dietary counseling aimed at reducing caloric intake by 100-300 calories per day)
Number of subjects: 54
Study: 21294203

Group type: EXPERIMENTAL
Intervention: Passiflora incarnata herbal tea
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 41
Study: 18772894

Group type: EXPERIMENTAL
Intervention: CLA (3 g daily) plus n-3 LC-PUFA (3 g daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control oil (6 g daily)
Number of subjects: 59
Study: 17719337

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1511
Study: 15213569

Group type: EXPERIMENTAL
Intervention: Sonagachi Project intervention (community organizing, advocacy, peer education, condom social marketing, health clinic establishment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sonagachi Project intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control community
Number of subjects: 200
Study: 11926074

Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed heuristic definition of 'bipolar spectrum disorder'
Number of subjects: 0
Study: 10202315

Group type: EXPERIMENTAL
Intervention: Theolong 400 mg/day
Number of subjects: 24
Study: 7771486

Group type: EXPERIMENTAL
Intervention: High blood flow (400 mL/min) for 2 hours with cuprophan membrane
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High blood flow (400 mL/min) for 2 hours
Number of subjects: 17
Study: 2250630

Group type: EXPERIMENTAL
Intervention: flunisolide + salbutamol
Number of subjects: 18

Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 18
Study: 6116855

Group type: EXPERIMENTAL
Intervention: PRP + P vaccine (with pertussis adjuvant)
Number of subjects: 64

Group type: COMPARATOR
Intervention: PRP vaccine alone
Number of subjects: 64
Study: 30325270

Group type: EXPERIMENTAL
Intervention: Lower body wearable resistance (LB) 5% body mass (BM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wearable resistance (1-10% BM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wearable resistance (5% BM and greater)
Number of subjects: 12
Study: 29226471

Group type: EXPERIMENTAL
Intervention: Cenderitide (4-hour infusion)
Number of subjects: 0
Study: 27382808

Group type: EXPERIMENTAL
Intervention: Storz DCI® video laryngoscopy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: GlideScope Cobalt® video laryngoscopy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: All laryngoscopes
Number of subjects: 65
Study: 25197997

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH) with Sodium Hypochlorite (NaOCl)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH) with Saline (control)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA) with Sodium Hypochlorite (NaOCl)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Mineral Trioxide Aggregate (MTA) with Saline (control)
Number of subjects: 128
Study: 22231479

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 144
Study: 19553088

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 326
Study: 17593074

Group type: EXPERIMENTAL
Intervention: Paracetamol (4 g daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15942808

Group type: EXPERIMENTAL
Intervention: Cyber visual training (Group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Instructor training only (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Instructor training with self-training (Group B)
Number of subjects: 36
Study: 12390373

Group type: EXPERIMENTAL
Intervention: Continuous rapidly absorbable suture
Number of subjects: 6566

Group type: COMPARATOR
Intervention: Continuous slowly absorbable suture
Number of subjects: 6566

Group type: COMPARATOR
Intervention: Non-absorbable suture
Number of subjects: 6566

Group type: EXPERIMENTAL
Intervention: Continuous sutures
Number of subjects: 6566

Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 6566
Study: 9554444

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 7748519

Group type: EXPERIMENTAL
Intervention: Ethanol + 1-tyrosine (TY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol + 1-tryptophan (TP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3189959

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30952736

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sodium bicarbonate mouthwashes (control)
Number of subjects: 75
Study: 28077104

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 60% of peak oxygen consumption
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Flutter® therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Resting breathing (control)
Number of subjects: 24
Study: 26373201

Group type: EXPERIMENTAL
Intervention: Neutral zone impression with maxillary denture in-situ
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neutral zone impression without maxillary denture in-situ
Number of subjects: 12
Study: 24016507

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 6520

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6520

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 6520
Study: 21347943

Group type: EXPERIMENTAL
Intervention: Nonbranded ads
Number of subjects: 0

Group type: COMPARATOR
Intervention: Branded ads
Number of subjects: 0
Study: 18505215

Group type: EXPERIMENTAL
Intervention: Sealing of margins
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Refurbishing
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Replacement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 66
Study: 16275015

Group type: EXPERIMENTAL
Intervention: Neutral shoe
Number of subjects: 10

Group type: COMPARATOR
Intervention: Varus and valgus shoes
Number of subjects: 10
Study: 14571005

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day) plus subcutaneous nadroparin (4100 units/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 40
Study: 10736073

Group type: EXPERIMENTAL
Intervention: 1% propofol plus 0.05% lidocaine at room temperature (20-23 degrees C)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 1% propofol plus 0.05% lidocaine cooled to 4C
Number of subjects: 70
Study: 8737760

Group type: EXPERIMENTAL
Intervention: Felodipine + Cyclosporine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Felodipine alone
Number of subjects: 12
Study: 8142113

Group type: EXPERIMENTAL
Intervention: Adapalene
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tretinoin
Number of subjects: 72
Study: 3728712

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alimentary odors
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nonalimentary stimuli
Number of subjects: 8
Study: 29605819

Group type: EXPERIMENTAL
Intervention: APIC intervention (weekly 3-hour personalised stimulation sessions for 12 months)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Control group (publicly funded universal healthcare services)
Number of subjects: 376
Study: 26020375

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg · kg(‐1) · day(‐1) divided every 12 hours) in addition to phototherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Phototherapy alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid with phototherapy
Number of subjects: 80
Study: 25727123

Group type: EXPERIMENTAL
Intervention: Positive depression screens
Number of subjects: 9765

Group type: EXPERIMENTAL
Intervention: Nonenrollment reasons
Number of subjects: 9765
Study: 23828106

Group type: EXPERIMENTAL
Intervention: NeuroFlo catheter treatment
Number of subjects: 100
Study: 21401537

Group type: EXPERIMENTAL
Intervention: iResus© application on a smart phone
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no smart phone)
Number of subjects: 31
Study: 19231633

Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 50 mg twice daily
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 100 mg twice daily
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 250 mg twice daily
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: A-002 (1-H-indole-3-glyoxamide) 500 mg twice daily
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 17157107

Group type: EXPERIMENTAL
Intervention: 150 microg levonorgestrel (LEV)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 250 microg norgestimate (NOR)
Number of subjects: 12
Study: 12626977

Group type: EXPERIMENTAL
Intervention: Sustained inflation with 45 cm H2O continuous positive airway pressure for 30 secs followed by postinflation positive end-expiratory pressure titrated from 20 cm H2O.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Postinflation positive end-expiratory pressure levels set at 16.7 +/- 2.3 cm H2O in ARDS(p) and 15.6 +/- 2.5 cm H2O in ARDS(exp).
Number of subjects: 24
Study: 10742877

Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Family group psychoeducation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Family therapy and Family group psychoeducation
Number of subjects: 25
Study: 9356569

Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 101
Study: 8458314

Group type: EXPERIMENTAL
Intervention: Metronidazole + High energy supplement (3.31 MJ daily for 3 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole (without energy supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard health care controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0
Study: 3743091

Group type: EXPERIMENTAL
Intervention: SHEP pilot study recruitment
Number of subjects: 551
Study: 29514613

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29956526

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by community pharmacists in collaboration with diabetologists and diabetes advisors
Number of subjects: 0
Study: 23809512

Group type: EXPERIMENTAL
Intervention: L-NMMA (nonselective NO-inhibitor)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22177399

Group type: EXPERIMENTAL
Intervention: Defusion technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thought suppression technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 0
Study: 20883502

Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope
Number of subjects: 400

Group type: COMPARATOR
Intervention: C-MAC
Number of subjects: 400
Study: 18693151

Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii (La1) supplementation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15783030

Group type: EXPERIMENTAL
Intervention: Roux‐Y duodenojejunal anastomosis (RY‐DJ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Roux‐Y choledochojejunostomy (R‐Y)
Number of subjects: 20
Study: 12051214

Group type: EXPERIMENTAL
Intervention: Standard textual patient information leaflet (PIL)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Alternate-form patient information leaflet with icons and graphs
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Hypothetical pain medication information leaflet
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group (traditional PIL)
Number of subjects: 196
Study: 10588565

Group type: EXPERIMENTAL
Intervention: Bupivacaine (15 mL 2.5 mg/mL) every 4 hours for 48 hours via catheter
Number of subjects: 41

Group type: COMPARATOR
Intervention: Saline (placebo) every 4 hours for 48 hours via catheter
Number of subjects: 41
Study: 9119355

Group type: EXPERIMENTAL
Intervention: Combined therapy (radiotherapy followed by melphalan and prednisone every 6 weeks for 3 years)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Radiotherapy alone (4000 to 5000 cGy)
Number of subjects: 53